ArticleJournal of translational medicine2026
The role of IFNLR1 in modulating T cell infiltration and cancer progression in renal cell carcinoma.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer, but reliable biomarkers for prognosis and immunotherapy response are lacking.
methodsWe analyzed type III interferon (IFN-λ) and its receptor IFNLR1 expression in ccRCC versus normal tissues using TCGA and GEO datasets, with IFNLR1 protein levels validated by tissue microarray. We investigated correlations between IFNLR1 and clinical features, prognosis, CD4
resultsIn ccRCC, IFN-λ expression is elevated while IFNLR1 is significantly reduced compared to normal tissues, as confirmed by tissue microarrays. Lower IFNLR1 levels correlate with advanced tumor stage, poor grade, and worse prognosis, and show positive association with CD4
conclusionIFNLR1 may serve as a potential prognostic biomarker for ccRCC, with its expression levels reflecting the tumor immune microenvironment. Its predictive value for clinical immunotherapy efficacy remains to be established in prospective clinical cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.